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Background: HPV vaccine coverage is far from ideal in Valencia, Spain, and this could be partially related to the
low knowledge about the disease and the vaccine, therefore we assessed these, as well as the attitude towards
vaccination in adolescent girls, and tried to identify independently associated factors that could potentially be
modified by an intervention in order to increase vaccine coverage.
Methods: A cross sectional study was conducted in a random selection of schools of the Spanish region of
Valencia. We asked mothers of 1278 girls, who should have been vaccinated in the 2011 campaign, for informed
consent. Those that accepted their daughters’ participation, a questionnaire regarding the Knowledge of HPV
infection and vaccine was passed to the girls in the school.
Results: 833 mothers (65.1%) accepted participation. All their daughters’ responded the questionnaire. Of those,
89.9% had heard about HPV and they associated it to cervical cancer. Only 14% related it to other problems like
genital warts. The knowledge score of the girls who had heard about HPV was 6.1/10. Knowledge was unrelated to
the number of contacts with the health system (Pediatrician or nurse), and positively correlated with the discussions
with classmates about the vaccine. Adolescents Spanish in origin or with an older sister vaccinated, had higher
punctuation. 67% of the girls thought that the vaccine prevented cancer, and 22.6% felt that although prevented
cancer the vaccine had important safety problems. 6.4% of the girls rejected the vaccine for safety problems or for
not considering themselves at risk of infection. 71.5% of the girls had received at least one vaccine dose. Vaccinated
girls scored higher knowledge (p = 0.05).
Conclusion: Knowledge about HPV infection and vaccine was fair in adolescents of Valencia, and is independent to
the number of contacts with the health system, it is however correlated to the conversations about the vaccine
with their peers and the vaccination status. An action to improve HPV knowledge through health providers might
increase vaccine coverage in the adolescents.
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Chronic infection with Human Papillomavirus (HPV) is
known to cause a range of pre-cancerous, cancerous and
being lesions like genital warts [1]. In Spain, cervical cancer
is the sixth most common malignancy, representing 4.8% of
all cancers in women. However its incidence is one of the
lowest worldwide (Predicted age standardized rate in 2012
of 11.6 cases per 100.000 women/year) [2] and the mortal-
ity rate of 2.7 per 100.000 women/year, similar to European
average [3,4].
HPV vaccines are highly efficacious in preventing
chronic infections and dysplasias by serotypes 16 and 18,
the most common oncogenic types [5-8].
Routine vaccination for all girls aged 14 years is recom-
mended in Valencia, since October 2008, and available free
of cost. However, the vaccine coverage decreased since its
implementation. In 2008, 85%, of the target population re-
ceived at least one HPV vaccine dose, and 73,9% received
all three doses. The following year coverage dropped to
66.1% for one and 63.3% for three doses. Factors that
could have influenced were: lack of awareness about the
infection, the impact of the media in relation to some al-
leged safety problems at the beginning of the vaccination
program [9], and concerns about vaccine effectiveness
promulgated by local critical groups [10].
It is therefore important to develop activities in order
to increase the vaccine coverage. As a first step we con-
sidered to assess the knowledge about the disease and
vaccine and the attitudes towards the vaccine in the tar-
get groups, so that could devise interventions directed to
the weaker points.
Worldwide many of the studies have examined individual
awareness, knowledge and attitudes towards vaccination.
Prior to the vaccine licensure, most of the studies reported
as most significant a lack of knowledge, and recurrent
myths, e.g. the impact of vaccination on promiscuity [11].
Subsequently, large vaccination campaigns in different
countries have had a favorable impact on the perception of
the vaccine to prevent disease. In the era post vaccine dis-
tribution, knowledge was positively associated with older
age, higher education, number of sexual partners, previous
diagnosis of cervical dysplasia or having ad an HIV test,
and it was negatively associated in the United States with
Latin American origin, opposition to premarital sex and
certain religious beliefs [12,13].
In several studies, summarized in a systematic review
there is a correlation between vaccine uptake and HPV
disease and vaccine knowledge, attitudes regarding vaccin-
ation and having a healthcare provider as a source of in-
formation [14]. However [15] there is not strong evidence
to recommend any specific educational intervention re-
lated to HPV vaccine for wide-spread implementation, as
the quality of the trials published so far is low and in liter-
ate populations, therefore future studies are required todetermine the effectiveness of culturally- competent inter-
ventions reaching diverse populations. In the same way, a
metanalysis found that individual interventions (not dur-
ing a health encounter) to inform or educate parents have
a low impact on their babies vaccine coverage, although
again the information is limited and of low quality, and
the main recommendation was to do this communication
as a complementary activity in a clinic [16].
There are few studies assessing the knowledge and atti-
tudes of exclusively young adolescents towards vaccin-
ation. This age group is important as the primary target
population for the vaccine delivery. At this age as girls be-
come more independent, their decision to be or not vacci-
nated is, at least, as important as their parents’ [17]. At
this age, less than 5% of the girls have had their first sexual
intercourse [18], and therefore their sexual history, an im-
portant driver for higher knowledge, is less relevant.
A recent report from colleges in the United Kingdom,
reported a low awareness and knowledge about HPV and
HPV vaccination in a cohort of girls that were offered the
vaccination through a school-based program [19].
The objective of our study was to assess the knowledge
and attitudes of 15 year-old Spanish girls (who were candi-
dates to receive the vaccine) towards HPV infection and
the vaccine, and to identify independently associated fac-
tors that could potentially be modified by an intervention.Methods
Design
A cross-sectional descriptive study in adolescent girls
(aged 15, born in 1995) was carried out. All data was col-
lected between September 2010 and May 2011. The girls
were eligible to receive and complete the HPV vaccine
series in the previous season (by June 2010).
Adolescent girls were recruited from primary schools of
the Province of Valencia, Spain. Schools were randomly
selected depending on the population for each of the
Counties of the Province, and included private and public
schools.
Both, mothers and girls completed an informed consent
forms prior to any research activity. Investigators sent the
informed consent to mothers through the school head
teachers. The teachers collected the forms. Schools were
paid €10 per each mother’s signed informed consent
collected.
Adolescents completed the study questionnaire in the
school, in the presence of one person from the research
team. Prior to distribution all participants received the
same information, and no further comments were made
after the questionnaire was handed to the girls to avoid
biasing the answers.
The Ethics Committee of the Center for Public Health
Research (CSISP), Valencia, Spain approved the study.
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A questionnaire, which consisted of 38 items, was devel-
oped. It assessed demographic information, social variables,
including religious affiliation and religious practice, and so-
cial status of the family as recommended by the Spanish
Epidemiology Association [20]. Use of health resources in-
cluded the number of times in the previous year that they
had a pediatric, GP, nurse or gynecologist consultation, and
whether they were followed up due to any chronic condi-
tion. Toxic consumption: smoking, cannabis, cocaine and
pills could have been ‘never consumed’, ‘consumed’, ‘seldom
consumed’ or ‘habitual consumption’. Awareness of social
problems was quantified using 5-points Likert scales (1 = no
concern to 5 = extremely concerned) in 9 questions, in-
cluding terrorism, epidemics, accidents, school failure and
safety. Awareness of health problems was also quantified
using the same Likert scales in 9 items, asking for concern
about cancer, infectious diseases (i.e. AIDS and STDs), de-
pression, new epidemics, diseases related to alcohol or
other drugs and obesity. Two scores were developed, a so-
cial awareness score and a health awareness score. Each
was calculated as the mean of the punctuation of the indi-
vidual items (1 to 5).
HPV disease and HPV vaccine awareness were assessed
by two items: ‘have you ever heard about HPV?’ and ‘have
you ever heard about the HPV vaccine?’.
HPV knowledge was assessed using a 16 closed ended
true/false items. By HPV knowledge we are referring to
the degree to which a person possesses and understands
objective information pertinent to HPV. To discourage
guessing by the participants, researchers instructed them
to choose ‘don’t know’. Distracter items, which assessed
higher level of understanding of HPV infection, were in-
cluded. These included an item to rule out the connection
between HPV and ovarian cancer. We also included true/
false statements (i.e. HPV produces hepatic cancer), to as-
sess knowledge discrimination through rejection of false
statements [21]. A knowledge summary score was com-
puted by assigning one point for each correct response
and zero points for each incorrect and ‘don’t know’ an-
swers. Points were summed to create a knowledge sum-
mary score.
HPV vaccine knowledge was assessed with five ques-
tions: ‘How many doses are required for a complete vac-
cination schedule’ and four closed ended true/false items
on the effect of the vaccine on future infections, the need
to use condoms, the need to follow genital screening and
the effect towards cervical cancer.
The means of receiving information about the vaccine
was assessed with the question: ‘where have you heard
about HPV vaccine?’.
Attitudes towards general vaccination were assessed
by a Likert scale in two questions asking about their atti-
tudes and their friends’, and also two open questionsasking about their beliefs regarding benefits and prob-
lems of vaccines.
HPV vaccination attitude was assessed by asking the
girls’ opinion about the vaccine, possible answers were:
‘it is a very good vaccine to prevent cervical cancer’, ‘it is
a vaccine that prevents cervical cancer but has problems’,
‘it is a good vaccine but is painful and I am frightened’ and
‘it is a vaccine for a disease I will never get’.
We also asked about the sources for vaccine informa-
tion (e.g., TV, press, radio, internet, brochures/leaflets,
pediatrician, nurse, parents and friends). A general sum-
mary question asked the girls to consider and select the
most relevant statement about the vaccine: ‘it is a very
good vaccine to prevent cervical cancer’, ‘it is a vaccine
to prevent cancer but it is problematic’, ‘it is a good vac-
cine but I am frightened because it hurts’, ‘it is a disease
I am never getting and therefore I am not receiving the
vaccine’. The answer to the number of vaccine doses re-
ceived was checked with the Valencian vaccine registry,
concordance was very high (Kappa = 0.92).
The questionnaire was piloted to validate comprehen-
sion among 15 girls in one school situated within a socio-
economic deprived area and used to validate the compre-
hension of the questions.Statistical analysis
For qualitative variables, number and percentage with its
normal 95% CI were calculated, with missing data in-
cluded in the calculation of percentages. Non-parametric
or ordinal variables were compared using the Mann–
Whitney-Wilcoxon test when comparing two groups, or
the Kruskal-Wallis test when comparing three or more
groups. Correlations were estimated between the HPV
knowledge summary score and all variables potentially re-
lated to knowledge. Pearson Product Moment Correla-
tions were calculated to estimate the relationship between
two continuous variables and Point-Biserial correlations
were calculated to estimate the relationship between a di-
chotomous variable (e.g., provider recommendation for
the HPV vaccine: yes or no) and a continuous variable
(HPV knowledge).
All data processing was performed using SPSS for
Windows (Version 15).
Questionnaire validation
Cronbach’s alpha was used to assess internal consistency
of each construct of the questionnaire. When the alpha
value was lower than 0.70, we considered that each of
the individual questions from these constructs actually
measured multiple unrelated psychological domains.
Questions from these constructs were considered indi-
vidually in the multivariate linear regression model of
predictors of parental HPV vaccine acceptability.
Table 2 Social and health concerns and toxic consumption
among adolescent girls in Spain
% 95% CI
Social-health worries*
Road traffic accidents 82.8 80.2-85.4
Terrorist attacks 76.5 73.6-79.4
Weight problems 59 55.7-62.3
AIDS 78.5 75.7-81.3
STDs 73.7 70.7-76.7
Toxic consumption
TOBACCO
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Sample
1278 mothers distributed among the schools were asked
for informed consent, 833 (65.1%) accepted participation,
in all those cases; their daughters fulfilled the question-
naire in the school and were included in the analysis.
Eighty percent of the adolescents lived with both par-
ents and their socioeconomic status was similar to that
occurring in Spain in 2010. Most of the parents (82.5%,
95% CI: 79.9-85.1%) were Spanish in origin and 11.3%
from South America. Over 85% of the girls were born in
Spain (Table 1).Never smoked 46.0 42.6-49.8
Consumed regularly 17.2 14.6-19.7
Alcoholic beverages
At least once 82.2 79.6-84.8
Consumed regularly 31.5 28.3-34.6
Cannabis
Never tried 79.4 76.6-82.2
Consumed regularly 3.9 2.6-5.2
*Percentage of responders that were worried or very worried with the social
or health problems.Adolescents’ concerns and attitudes towards social and
health problems
Among the social problems that girls were concerned
about, school and sport accidents were the least rated,
while those more severe or with higher media impact were
of highest concern: road traffic accidents and terrorist at-
tacks (Table 2). Concerns about health problems were di-
verse, being the weight problems the most rated (Table 2),
with 78.5% (95%CI: 75.7-81.3%) of the girls being worried
about it.Table 1 Characteristics of the study participants
N %
Country of birth
Spain 716 86.0
Other 116 14
Current family status
Living with both parents 658 79.0
Parents divorced/separated 138 16.5
Father or mother widow 25 3.0
Other 12 1.4
Religious beliefs
Practising 117 0.14
Occasional practising 133 16.0
Non-practising 303 36.4
Non-believer 215 25.8
No answer 65 7.8
Parents occupation Father (%) Mother (%)
Unemployed 52 (6.9) 12 (1.6)
Undergraduate/director >10 187 (24.7) 117 (15.5)
Postgraduate/director <10 30 (4.0) 87 (11.5)
Admin./self-employed 171 (22.6) 100 (13.2)
Qualified technician 176 (23.5) 97 (12.8)
Semi-qualified technician 38 (5.0) 33 (4.4)
Unqualified worker 100 (13.2) 311 (41.1)
Study sample n = 833.Tobacco consumption is high among the adolescent
girls as 17.2% (95% CI: 14.6-19.7%) consumed it regularly
(Table 2). Alcoholic beverages had been drunk, at least
once, by 82.2% (95% CI: 79.6%-84.8%) and cannabis con-
sumed regularly by 3.9% (95% CI: 2.6-5.2%). There was a
high linear correlation between tobacco and cannabis
consumption (p < 0.001). Tobacco consumption was un-
related to the concerns that girls had about cancer, alco-
hol or tobacco related diseases, weight problems, AIDS
or STDs, as well as school failure or depression.
Knowledge, attitudes and beliefs towards HPV infection
and vaccination
The majority of the study participants (89.9%) had heard
about HPV infection and knew its association to female
genital cancer, and all of them associated HPV with cer-
vical cancer; although 39.1% (95% CI: 35.8%-42.4%) also
associated HPV with ovarian cancer. A lower percentage
of girls had knowledge about the role of HPV infection
among males with 5.5% (95% CI: 3.9%-7.0%) relating it
with penis cancer and 26.9% (95% CI: 26.8%-33.0%) re-
lated it to a male infection (Table 3).
Only 14% (95% CI: 11.6%-16.4%) of the girls knew the
association between HPV and genital warts.
Most of the girls (86.2%; 95% CI: 83.8-88.5%) of the
total sample were aware of the mechanism of transmis-
sion of the infection and 61% (95% CI: 57.7-64.3%) did
not consider themselves to be at risk of infection.
With regards to potential ways of avoiding the dis-
eases, 83.9% (95% CI: 81.4-86.4%) considered the use of
Table 3 Knowledge of adolescents in relation to HPV and
HPV vaccine (n = 833)
Yes (%) No (%) Don’t
know (%)
Diseases related to HPV
Penis cancer 46 (5.5) 628 (75.4) 159 (19.1)
Ovarian cancer 326 (39.1) 314 (37.7) 193 (23.3)
Genital warts 117 (14.0) 438 (52.6) 278 (33.4)
Cervical cancer 750 (90.0) 22 (2.6) 61 (7.3)
Transmission
Lack of hygiene 29 (3.5) 683 (82.0) 121 (14.5)
Intimate kissing 19 (2.3) 706 (84.8) 108 (13.0)
Transmitted by boys 224 (26.9) 425 (51.0) 184 (22.1)
Sexual intercourse 718 (86.2) 26 (3.1) 89 (10.7)
Ways of preventing HPV diseases
Hand washing 67 (8.0) 551 (66.1) 214 (25.7)
Good hygiene 429 (51.9) 273 (32.8) 130 (15.6)
Condoms 699 (83.9) 45 (5.4) 88 (10.6)
Cannot be prevented 104 (12.5) 389 (46.7) 338 (40.6)
HPV vaccine
If vaccinated I will never
get HPV infection
289 (34.7) 539 (64.7) 5 (0.6)
If vaccinated I will not
need condom any longer
in sexual intercourses
10 (1.2) 821 (98.6) 2 (0.2)
If vaccinated I will need
cervical cancer screening
789 (94.7) 42 (5.0) 2 (0.2)
HPV vaccine completely protects
against cervical cancer
211 (25.3) 612 (73.5) 10 (1.2)
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giene avoided infection, and 12.5% (95% CI: 10.2-14.7%)
considered that HPV infection could not be avoided.
The mean of the knowledge score, in those girls that
had heard about HPV before the questionnaire, was 6.1
out of 10. It was positively related to the girl being Spanish
in origin (p = 0.015) and having older sisters that had re-
ceived the HPV vaccine (p = 0.016), and it was unrelated
to their religious affiliation or health care attendance.
Most of the girls had heard about the HPV vaccine
(97.4%; 95% CI: 96.3-98.5%), although some of them did
not know what HPV was. With respect to beliefs and atti-
tudes towards HPV vaccination, 539 (64.7%; 95%CI: 61.4-
67.9%) knew that the vaccine potentially protected against
any HPV infection and 25% (95%CI: 22.1-27.9%) thought
that the vaccine completely protected against cervical cancer.
The utility of condoms, after vaccination, as protective
barrier during sexual intercourse was reported by 821
(98.5%; 95% CI: 97.7-99.3%). Of the 833 girls, 789
(94.7%; 95% CI: 93.2-96.2%) thought that, despite vaccin-
ation, cervical screening was needed for secondary
prevention.Do girls talk with their peers about the vaccine?
771 adolescents (92.6%; 95%CI: 90.8-94.4%) had recently
spoken with classmates or friends about the vaccine. The
most common topic was that the vaccine hurt (82.4%; 95%
CI: 79.8-84.9%), it was very reactogenic (78.3%; 95%CI:
75.5-81.1%) and that it was a source of diseases (71.3%;
95%CI: 68.2-74.4%), but also that it was a very good vac-
cine to prevent cancers (73.1%; 9%CI: 70.1-76.1%). The
overall positive comment among adolescents, that the HPV
vaccine was very good, was a matter of discussion in 59.4%
(95%CI: 56.1-62.7%) of the cases.
In general, adolescents concurred with the statement
that the vaccine was very good for preventing cancers,
558 girls (67%; 95% CI: 63.8-70.2%); 22.6% (95% CI: 19.7-
25.4%) felt that, although it prevented cancer, it had im-
portant problems. And 6.4% (95% CI: 4.7-8.1%) of the
girls thought that they would definitely not have the vac-
cine because of the adverse events, and 3.2% (95% CI:
2.0-4.4%) because they were not at risk of infection.
There was a good positive correlation between adoles-
cents discussing the vaccine with their peers and their
knowledge score (p < 0.05).
Health system utilization: impact on HPV knowledge and
vaccine attitude
During the previous year, 699 girls (84%; 95% CI: 81.5-
86.5%) had visited their GP or primary care pediatrician,
63% (95% CI: 59.7-66.3%) more than once; 51% (95% CI:
47.6-54.4%) attended a nurse clinic in primary care.
Of the 833 girls of the total sample, 12% (95% CI: 9.8-
14.2%) were followed up for chronic conditions, primar-
ily allergies and asthma and, less frequently, scoliosis or
migraine.
A small percentage, 7% (95%CI: 5.3-8.7%), acknowledged
not having received all the recommended vaccines during
childhood or was unaware of their vaccination status.
In general, the adolescent population were positioned
positively for vaccination, with only 1% (95% CI: 0.3-
1.7%) completely against vaccination, 2.4% (95% CI: 1.4-
3.4%) not being very positive, and 21.0% (95% CI: 18.2-
23.8%) were indifferent towards vaccination with a very
strong association between their belief on vaccination
and their peers’ (p < 0.001).
The number of visits to the GP/pediatrician or nurse
was unrelated to the knowledge score, the social and
health awareness scores or their beliefs about HPV in-
fection and the vaccine.
Vaccination status: 596 girls had received at least one
vaccine dose at the time of the questionnaire (71,5%;
95% CI: 68.5-74,6%), and scored higher knowledge than
non vaccinated (6.02 vs. 5.75; p = 0.05).
Only other two variables were significantly correlated
with HPV knowledge: parents being of Spanish origin
and having a sister that had been previously vaccinated.
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knowledge score and accounted for 5.8 of the variance
in HPV knowledge score.
Questionnaire validation
Internal reliability estimates were calculated for each
construct and found to be adequate for the Social aware-
ness, disease awareness and HPV knowledge with a
Cronbach’s alpha between 0.86 and 0.78.
Discussion
This study showed that adolescent girls in Spain had a
fair knowledge about HPV infection and its prevention,
with still important gaps, to remark the unbalanced per-
ceived safety profile of the vaccine and that many do not
consider themselves at risk of infection.
An important finding was the lack of relation between
the girls’ knowledge and their attendance to the health
system, and no correlation with the number of visits to
either the pediatrician or the nurse, this meant that ei-
ther the health provider did not invest time in discussing
these facts or the explanation was not understood.
There are studies [22] where health care utilization is a
positive predictor for vaccination, however there are areas
where the provider recommendations are limited [23,24].
In Vadaparampil’s survey [24], over half of the pediatricians
questioned in the United States had a low knowledge on
HPV and perceived vaccine safety as a barrier for vaccin-
ation. However this finding was unrelated to their recom-
mendation, as over 75% of the pediatricians followed the
vaccine schedules, and recommended HPV vaccine in
most of the visits for this age group of girls.
Unlike the impact of pediatricians or nurses on HPV
knowledge, there is a strong correlation with peer discus-
sions. This is an important finding as the information in this
age group might come from less accurate sources and with-
out quality filters. A review of Internet sources showed than
both German and Spanish websites lacked balanced report-
ing on the completeness, transparency and exact dimen-
sions of HPV and HPV vaccination [25]. Unbalanced media
coverage may fuel vaccine alarm, and be shared among
peers without any interaction with health care providers/sys-
tem and may pose a risk to HPV vaccination programs.
In our study vaccinated girls scored higher in the know-
ledge construct, however whether higher knowledge was a
driver for vaccination or the fact of being vaccinated sup-
possed higher knowledge (by instance the number of vac-
cine doses) is unknown. Adolescent and parents’ knowledge
about HPV and HPV vaccination are frequently associated
with vaccine uptake [14,26-28]. Although still not proven,
an intervention to promote HPV vaccine knowledge may
reduce one of the barriers for HPV vaccination. A recent
German trial suggested that balanced information to
the parents and girls, through brochures, increased theknowledge about HPV, but did not increase the vaccine up-
take when compared to a group not receiving adequate in-
formation [29]. However, this last measurement, analyzed
one year after the informative period, might be diluted by
the mixing of both groups in the same classrooms, where
information is shared and discussed. A systematic review
that assessed the educational interventions used to in-
crease HPV vaccine acceptance [15] showed that due to
the quality of most of the trials and the population tar-
geted, there is no evidence that increasing the knowledge
about HPV does not improve vaccination coverage, there-
fore further studies of higher quality are required.
With the recommendation that vaccine be administered
at age 14, young adolescent girls, may consider vaccination
as one of their first health related decisions. In fact, al-
though most of the times parents think that vaccinating
their adolescent daughters should be their decision [30,31],
in some studies parents agreed that a well-informed child
should be able to request HPV vaccination without paren-
tal consent [17]. Therefore, timely knowledge about the
disease and the vaccine seems to be an important factor
for vaccine program success.
From our study, knowledge is unrelated to other
health concerns like cancer or traffic road accidents, or
to other social concerns like terrorism. It seems that the
way adolescents look at HPV is rather unusual and it is
possibly because HPV is new in their lives and, although
they might have heard about the virus, there is little con-
cern about it.
The only factors independently associated with know-
ledge were not modifiable, being Spanish in origin and hav-
ing an older sister vaccinated. Spanish girls do not have an
easier access to vaccines, as vaccines are given for free to
all subjects living in Spain, therefore the explanation that
immigrant population know less about the disease is not
due to a lack of contact with the health system or lower
education, as we passed the questionnaires in schools.
There are descriptions in the USA of Latin American girls
being less vaccinated, and it is possibly due to cultural or
traditional barriers rather than having less facilities [32].
Our girls perceive HPV vaccination as a vaccine for STD
more than a vaccine to prevent cervical cancer, and this is
partially expected by their adolescent condition. Their atti-
tude towards the vaccine is more intuitive than reasoned,
in an exercise that mix correct and incorrect knowledges.
This study has some limitations. A systematic review
[33] concluded that differences among studies results
might be partly explained by variations in the question-
naires and lack of validation or analysis of consistency.
We piloted the questionnaire to validate comprehension,
however it is possible that not all girls fully understood all
questions. We included questions previously validated in
other studies and found that the internal consistency of
the constructs was high.
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the recruitment was difficult as we needed to obtain an in-
formed consent from mothers and informed assent from
the girls, and the former were difficult. The head teachers
had to contact parents through the girls. We were unable
to assess whether the responders differed from the non-
responders, and that might have biased the results. School
attendance is compulsory in Spain until the age of 16
therefore the universe of girls aimed for the questionnaire
equaled the teenage population of Spain. In order to assess
the representativity of our sample we compared our re-
sults with those of the National Institute of Statistics, and
the distribution of our girls mirrored the general popula-
tion in regards to the parent’s job [34] as well as the origin
of the family. With reference of the toxic consumption we
compared our results with the last published national
health survey (2011–2012) [35].
In this survey data from women 15 to 24 years of age is
aggregated, tobacco consumption in this group was 20,95%,
slightly higher than our confidence interval. With regards
to alcohol consumption, in the survey 20.5% of this group
drank at least weekly, which is a lower figure that our sam-
ple’s answer to regular consumption. From the vaccination
point of view, our sample had slightly higher vaccination
coverage than the official figure for at least one vaccine
dose (75% vs 66.5%). We considered that the sample was
not very different to the general population as there was no
a tendency to higher or lower toxic consumption, and also
the age group we compared was not exactly the same.
Therefore the fact that only 65% of the mothers signed the
informed consent could bias the results but our estimation
is that their representativity was high.
Conclusion
In conclusion, knowledge about HPV and it prevention
is fair in Spanish adolescents, although they had import-
ant gaps. Their information is unrelated to the number
contacts with the health system but to their discussions
with peers, which might pose the vaccination program
at risk in case of spurious associations.
Acceptability might increase if misleading information
is explained and discussed with health providers that
might devote a longer time to explain the disease and
vaccine to adolescents. However this activity should be
further evaluated.
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